本帖最后由 老马 于 2013-3-13 13:43 编辑
; A: I% c6 x# S! w: M' W, ?9 e5 }% B$ L
健择(吉西他滨)+顺铂+阿瓦斯汀8 {6 M0 \( _9 B7 b- w
Gemzar +Cisplatin + Avastin
2 x g1 \0 O2 ~! D% B, _http://annonc.oxfordjournals.org/content/21/9/1804.full
8 F M6 R# A+ K0 x+ I. P8 N* W7 XOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& w" [ w6 ^' e, _: j0 sPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
C0 g y& q7 K: f" p" y; K( HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; J9 f7 Z7 y; C! p
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 844)
; E4 L$ ]4 J% C华为网盘附件:
) n7 U$ B1 B6 c【华为网盘】ava.JPG2 ]% a, @7 r, e5 A3 Z. S
|